We examined the hypothesis that the dopamine D 3 receptor gene (DRD3) is a susceptibility factor for cocaine dependence. The MscI /Bal I polymorphism of the DRD3 gene was examined in 47 Caucasian subjects with cocaine dependence and 305 Caucasian controls. Based on prior studies with a range of psychiatric disorders we hypothesized there would be a decrease in the frequency of the 12 genotype in the patient sample (increased homozygosity). We observed a significant decrease in the frequency of 12 heterozygotes in subjects with cocaine dependence (29.8%) vs controls (46.9%) (P Յ 0.028). This percentage was still lower in those who had chronically used cocaine for more than 10 years (25%), or more than 15 years (21.5%). The DRD3 gene accounted for 1.64% of the variance of cocaine dependence. The DRD2 gene had an independent and additive effect on cocaine dependence. These findings support a modest role of the DRD3 gene in susceptibility to cocaine dependence.
Caine and Koob 1, 2 have shown that the pretreatment of rats with the dopamine D 3 agonist 7-OH DPAT shifted the cocaine self-administration dose-effect to the left, suggesting that D 3 receptor stimulation enhances the reinforcing effect of cocaine. Conversely, the self-administration of 7-OH DPAT in rhesus monkeys is modified by prior exposure to cocaine. 3 Some studies in humans also suggest a potential role of the D 3 receptor in cocaine dependence. For example, the D 3 receptor is present in high density in the nucleus accumbens; the prime site of dopamine reward pathway. Its density in this area is two-fold higher in victims of accidental cocaine overdose. 4, 5 These observations suggest that cocaine use leads to a neuroadaptive elevation in D 3 receptor density in response to increased synaptic dopamine 6 and that the D 3 receptor may be one mediator of the reinforcing effects of cocaine. 1, 2 We hypothesized that if the D 3 receptor plays a role in cocaine dependence, then the DRD3 genotype frequencies might be different in cocaine-dependent individuals than in controls. A MscI (BalI) polymorphism resulting in a substitution of glycine→serine in the first exon of the DRD3 gene has been described by Lannfelt et al. 7 Crocq et al 8 reported a decrease in 12 heterozygosity for this polymorphism and an increase in 11 and 22 homozygosity in subjects with schizophrenia vs controls. Some studies have supported this finding while others have not. In a review of the role of the DRD3 gene in schizophrenia, Asherson et al 9 reported that when they combined their results with those in the literature there was a significant decrease in 12 heterozygosity in males (P = 0.00021) but not in females (P = 0.60), indicative of an important sex effect at this gene in schizophrenia. We have observed a significant decrease in DRD3 MscI 12 heterozygosity in Tourette syndrome 10 and pathological gambling. 11 The studies of Jö nsson et al 12 showed that the mean HVA level for the 11 + 22 DRD3 homozygotes was 190 nmol L −1 compared to 161 nmol L −1 for the 12 heterozygotes (P = 0.08). Recently Krebs et al 13 reported a significant decrease in DRD3 BalI heterozygosity in 36 schizophrenics with comorbid substance abuse (30.6%) compared to 52 controls (51.9%). They then compared 54 opiate addicts to 70 controls.
14 There was a significant decrease in DRD3 BalI 12 heterozygosity (23.6%) in a subgroup of 38 opiate addicts with a Zuckerman sensation-seeking score of greater than 24 compared to controls (44.3%), or opiate addicts with a sensationseeking score of Յ24 (64.2%). Freimer et al 15 found a non-significant trend for a decrease in DRD3 MscI 12 heterozygosity in 62 Caucasian (35.5%) and 62 African-American (33.8%) subjects with cocaine dependence compared to 61 Caucasian (42.6%) and 29 African-American (41.4%) controls. These combined observations led us to test the hypothesis that there would be a significant decrease in 12 heterozygosity (negative heterosis) in subjects with cocaine dependence. Table 1 shows the comparison of the 11, 12 and 22 genotypes and the percentage of 12 heterozygotes in the controls vs cocaine users. The frequency of the 12 genotype was 46.9% in the 305 controls vs 29.8% in those with cocaine dependence (P Յ 0.028). The percentage of 12 heterozygotes decreased to 25.0% in those using cocaine for more than 10 years and to 21.4% in those using cocaine for more than 15 years. By comparison, for those with amphetamine dependence but not cocaine dependence, the frequency of 12 heterozygotes was 33.3% (P Յ 0.20). For those with opioid dependence and not cocaine dependence it was 41.7% (P Յ 0.72), and for those with alcohol dependence but not cocaine dependence, it was 38.5% (P Յ 0.26). Using univariate regression analysis of the DRD3 gene variable vs the cocaine variable, r 2 = 0.0165, P Յ 0.02, indicating that the DRD3 gene contributed to a significant but modest percentage of the variance of cocaine dependence.
These results are consistent with a role of the DRD3 gene in susceptibility to cocaine addiction in humans. Susceptibility to drug addiction is undoubtedly multifactorial with both polygenic and environmental fac- tors playing a role. [16] [17] [18] In our experience with studies of the association of many genes with various behavioral disorders, we find that each gene rarely contributes to more than 2% of the variance of a given trait. 19 This was also the case in the present study where the percentage of the variance accounted for by the DRD3 gene was 1.64. Studies of Noble et al 20 specifically examining cocaine dependence, or of ours 21 and others 22, 23 examining drug dependence in general, suggest that another dopamine receptor gene, DRD2, is also involved. To determine if the present results were actually due to the presence of the DRD2 gene Taq A1 allele, we examined the cocaine addicts and SB controls at the DRD2 gene. 21 In this group the DRD3 gene accounted for 1.64% of the variance of the cocaine variable and the DRD2 gene (11 or 12 genotype = 1, 22 = 0) accounted for 1.76% of the variance. When the two gene scores were added together to form a DRD2/DRD3 gene score ranging from 0 to 2, they accounted for 3.62% of the variance (P Յ 0.009). This indicated the two genes were independent and additive in their effect on cocaine dependence and the effect of the DRD3 gene was not due to a hidden effect of the DRD2 gene.
A second issue was whether the three sets of controls we used were representative of Caucasians in general. To test this we examined the world literature on the frequency of the DRD3 MscI/BalI 12 genotype in Caucasians. There were a total of 1781 Caucasian controls in 10 different countries. The mean frequency of the 12 heterozygotes was 47.2%, virtually identical to the 46.9% in our 305 controls. These studies are diagrammed in Figure 1 , summarizing both the frequency of the 12 heterozygotes and the number of subjects in each study and comparing them to the three groups of cocaine addicts.
Duaux et al 14 found no association between the DRD3 gene and their total group of opioid addicts, but did observe a significant decrease in 12 heterozygosity in those with a Zuckerman sensation-seeking score of Ͼ24. Since the Zuckerman test was not administered to our substance abusers we were not able to perform a similar analysis. However, cocaine abusers are known to score high on the sensation-seeking score.
24,25
The animal studies reviewed above imply that D 3 receptor stimulation enhances the reinforcing effect of cocaine. The studies of Jö nsson et al 12 suggest that the presence of the 11 or 22 genotype is associated with increased dopaminergic activity. Thus, the significant increase in subjects with the 11 or 22 genotype, or a decrease in frequency of the 12 genotype, in cocaine users would be consistent with an enhanced reinforcing effect of cocaine in such subjects. Since the number of cases in this study was relatively small, a replication of these findings with a larger number of subjects with chronic cocaine dependence is needed.
Methods

Subjects
The Addiction Treatment Unit is the inpatient addiction treatment center of the Jerry L Pettis Veterans Administration Hospital in Loma Linda, California. Between 1994 and 1997, all new admissions to the ATU who gave informed consent were entered into a National Institute of Drug Abuse sponsored study of genetic factors in drug abuse/dependence. Since these inpatients are long-term drug users, their substance abuse problems tend to be more severe than samples seen in the average outpatient treatment program. Assessments included a trained interviewer-administered Diagnostic Interview Schedule 26 Version III Revised (DIS-IIIR) to provide lifetime DSM-IIIR diag- noses in most of the subjects, and the Addiction Severity Index (ASI), 27 a semi-structured, clinician-administered interview that collects data from substance abusers in multiple problem areas, was administered to all subjects. Subjects with cocaine dependence were those who fulfilled the DSM-IIIR criteria for cocaine dependence. For those who were not given the DIS-IIIR, the diagnosis of cocaine dependence was based on the final discharge diagnosis of staff psychiatrists. Based on the ASI, two subsets of cocaine addicts were also examined, those with a history of more than 10 years of cocaine use, and those with a history of more than 15 years of cocaine use. The mean age of the ATU subjects was 38.5 years (SD 7.3) and 93% were male. To avoid the confounding problems of racial stratification, all subjects were non-Hispanic Caucasians. Fifty-two percent of the subjects with cocaine dependence had comorbid affective disorder and 32% had comorbid simple or social phobia.
Controls
The control group consisted of three groups: (a) students from the California State University at San Bernardino (SB controls) (n = 140); (b) adoptive or foster parents of children with Tourette syndrome or ADHD unrelated to the probands (n = 74) (COH controls); (c) unrelated CEPH (Centre d'etude du Polymorphisme Humain) grandparents (n = 91). The latter is a publicly available set of banked DNA samples used in linkage studies. While histories of possible cocaine or other drug dependence were not available for the CEPH samples, the presence of a few subjects with cocaine dependence would presumably decrease rather than increase differences between our total controls and cocaine-dependent subjects. The CEPH samples have the advantage that they are widely available and the genotyping can be independently replicated. All SB controls were administered the MAST-R 28 (MAST for alcohol use revised to include drug use) to screen for drug and alcohol use and those with a score of more than 5 were excluded. All the COH controls were personally interviewed and administered a questionnaire based on the DSM-IIIR criteria for drug and alcohol abuse/dependence and those with any substance abuse problems were excluded. A family history of drug or alcohol abuse/dependence was only available on the COH controls and here those with a positive family were excluded. By chi-square analysis there were no significant differences in the 12 heterozygote frequency in these three control groups, which ranged from 44.3 to 50.5%. The mean age of the controls was 38.1 years (SD 11.41). All individuals in the ATU and control samples signed written informed consents.
Comparison groups
To test the primary hypothesis, the frequency of the 12 heterozygotes was compared in the total control group vs cocaine-dependent cases. To examine the possibility that the frequency of the 12 heterozygotes might decrease with increased years of use, the following two subsets of this group were examined: (a) only those who had been using cocaine for more than 10 years; and (b) those who had been using cocaine more than 15 years.
Since amphetamines also interact with dopaminergic neurons, we sought to determine if any association with the DRD3 gene was specific to cocaine or might apply to amphetamine dependence as well. Thus, we examined those ATU subjects who had a DIS diagnosis of amphetamine dependence but not of cocaine dependence. To compare the role of the DRD3 gene in other types of substance dependence, we also examined those with a DIS diagnosis of opioid dependence but not cocaine dependence, and of alcohol dependence but not cocaine dependence.
Genotyping
The region of the polymorphism was amplified by PCR using the primers and technique described by Lannfelt et al 7 with minor modifications.
Statistics
The frequency of those carrying the 12 genotype was compared in the above groups by two-tailed exact chisquare analysis using the StatXact program (Cytel Software Corporation, Cambridge, MA, USA). To obtain an estimate of the percentage of the variance of cocaine dependence accounted for by the DRD3 gene, two variables were set up. The first was a DRD3 gene variable where those with the DRD3 12 genotype = 0, and those with a 11 or 22 genotype = 1. The second was a cocaine variable where those with cocaine dependence =1, and the controls =0. Univariate regression analysis was used to determine the r, r 2 , F and P for these correlations.
